KOE:950160

Kolon TissueGene, Inc. · KOE · Healthcare · KRW · FY for 2025

Figures on this page computed 2026-11-08 13:21 UTC

Last close

n/aKRW

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-3733.3%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-488.7%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
1.24Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed

Safety is the furthest below its sector's middle: 0.16 against 0.58 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

1.06x

3.42x

0.46x

3.59x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales1.06x
Its own average over 7 years, 4.85B.
Profit3.42x
Its own average over 7 years, -56.25B.
Free cash flow0.46x
Its own average over 6 years, -54.91B.
Debt3.59x
Its own average over 6 years, 22.23B.
Pricen/a
Its own average over 0 years. Market data

Debt is furthest from its own average, at 3.59 times.

Sales is 1.06 times its own 7-year average; Profit is 3.42 times its own 7-year average; Free cash flow is 0.46 times its own 6-year average; Debt is 3.59 times its own 6-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 7-year average1.06
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Profit against its own 7-year average3.42
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Free cash flow against its own 6-year average0.46
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Debt against its own 6-year average3.59
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
KRW